{"version":"1.0","type":"link","title":"Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.","author_name":"Tsimafeyeu I 외","author_url":"https://prs-insight.online/author/Tsimafeyeu%20I","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167286","thumbnail_width":1200,"thumbnail_height":630}